KRAS and colorectal cancer: In terms of ongoing trials, EV are currently being tested for the treatment of advanced hepatocellular carcinoma and liver metastasis of gastric and colorectal cancer (NCT05375604, EVs loaded with STAT6 antisense oligonucleotides), metastatic pancreatic cancer with a KRAS G12D mutation (NCT03608631, EVs loaded with KRAS G12D siRNA), and colon cancer (EVs loaded with curcumin).